Amylyx reports no serious side effects in first group of ALS trial (opens in new tab)

Amylyx will present data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS Meeting 2026, held 24-26 June in Madrid. AMX0114 was generally well tolerated in Cohort 1 (12.5 mg) with no drug-related serious adverse events and no serious neurological adverse events, findings the company says support […] The post appeared first on <a href="